MedTrace Logo

Drug Use Investigation for REVOLADE (ITP)

NCT01416311 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5797

Last updated 2020-11-20

No results posted yet for this study

Summary

To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety and efficacy.

\<Priority investigation item\> Thromboembolism

Conditions

  • Purpura, Thrombocytopaenic, Idiopathic

Interventions

DRUG

Eltrombopag

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-21
Primary Completion
2020-10-16
Completion
2020-10-16

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01416311 on ClinicalTrials.gov